Effects of Ambovir combined with amlodipine besylate on urinary protein, serum creatinine, and serum uric acid levels in patients with renal hypertension

Abstract

Objective To investigate the effects of Ambovir combined with amlodipine besylate on urine protein, serum creatinine, and serum uric acid levels in patients with renal hypertension. Methods Eighty-two patients with renal hypertension admitted to our hospital from January 2017 to August 2019 were divided into two groups with the two-color ball grouping method: control group and study group. The control group was treated with amlodipine besylate, and the study group was treated with Ambovir combined with amlodipine besylate. The urinary protein, serum creatinine, and serum uric acid levels were compared between the two groups. The clinical efficacy and the adverse drug reactions of the two groups were compared. Results Before treatment, there were no statistically significant differences in, serum creatinine, serum uric acid, and urine protein levels between the control group and the study group [(348.06±68.15) μmol/L, (453.45±20.25) μmol/L, (1.78±0.56)g/L; (348.08±68.24) μmol/L, (452.05±20.47) μmol/L, (1.79±0.55)g/L] (P>0.05). The levels of the above indicators improved after treatment in the control group and the study group [(321.25±40.26) μmol/L, (415.13±18.25) μmol/L, (1.64±0.51)g/L; (271.24±29.45) μmol/L, (363.15±12.34) μmol/L, (1.44±0.32)g/L], those in the study group were more ideal (P 0.05). The clinical effective rate was 73.2% in the study group and 48.8% in the control group, the study group was superior to the control group (P<0.05). Conclusion The combination of Ambovir and amlodipine besylate can improve clinical efficacy in the clinical treatment of renal hypertension, reduce urine protein, serum creatinine, and blood uric acid levels, and will not increase adverse drug reactions, which is worthy of clinical application. Key words: Ambovir; Amlodipine besylate; Renal hypertension; Urinary protein; Serum creatinine; Serum uric acid